0.130
-0.015
(-10.34%)
Delayed:
9:48AM EDT
OTCBB
data delayed by 15 mins -
Disclaimer
Currency in USD
| Range | 0.13 - 0.14 |
| 52 week | 0.09 - 0.18 |
| Open | 0.14 |
| Vol / Avg. | 460,500.00/112,982.00 |
| Mkt cap | 32.72M |
| P/E | - |
| Div/yield | - |
| EPS | -0.04 |
| Shares | 251.69M |
| Beta | 1.28 |
| Inst. own | 47% |
Events
Aug 5, 2013
Q2 2013 Aradigm Corporation Earnings Release
May 22, 2013
Aradigm Corporation Annual Shareholder Meeting
May 14, 2013
Q1 2013 Aradigm Corporation Earnings Release
|
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -1191.76% | -816.88% |
| Operating margin | -1050.90% | -665.74% |
| EBITD margin | - | -623.54% |
| Return on average assets | -178.98% | -84.27% |
| Return on average equity | - | - |
| Employees | 11 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Aradigm Corporation is a specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. The Company's lead development candidates are formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)), which is delivered by inhalation for the management of infections associated with the severe respiratory diseases cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE).
Officers and directors
| Virgil D. Thompson | Independent Chairman of the Board | |
| Igor Gonda Ph.D. | President, Chief Executive Officer, Director | |
| Nancy E. Pecota | Chief Financial Officer, Vice President - Finance | |
| Frank H. Barker | Independent Director | |
| Tamar D. Howson | Independent Director | |
| John M. Siebert Ph.D. | Independent Director |